Overview
NICE is unable to make a recommendation on sarilumab (Kevzara) for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years. This is because the company did not provide an evidence submission.
Last reviewed: 22 October 2025
Next review: We will review this decision if the company decides to make a submission.